<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842176</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-BREAST-CTC</org_study_id>
    <nct_id>NCT03842176</nct_id>
  </id_info>
  <brief_title>Clinical Application of CTC in Operable Breast Cancer Patients</brief_title>
  <official_title>Clinical Application of CTC in Operable Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the possibility of clinical application of CTC detection in&#xD;
      samples or peripheral blood of breast cancer patients, so as to act as the new techniques or&#xD;
      indicators of early diagnosis, therapy efficiency, or postoperative surveillance of breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The level of CTC mRNA markers in patients' peripheral blood</measure>
    <time_frame>3 years</time_frame>
    <description>The level of CTC mRNA markers in patients' peripheral blood of neoadjuvant chemotherapy group and surgery group in different periods</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <description>CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <description>CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy before surgery</intervention_name>
    <description>The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery followed by adjuvant chemotherapy</intervention_name>
    <description>The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Operable breast cancer patients who need chemotherapy before or after surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained and documented according to the local&#xD;
             regulatory requirements prior to beginning specific protocol procedures.&#xD;
&#xD;
          -  Age of at least 18 and at most 70 years.&#xD;
&#xD;
          -  Performance status (Karnofsky-Index) &gt;80%.&#xD;
&#xD;
          -  Chemotherapy is necessary before or after surgery.&#xD;
&#xD;
          -  No clinical evidence of local recurrence or distant metastases.&#xD;
&#xD;
          -  Complete staging work-up within 3 months prior to registration. All patients must have&#xD;
             (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed as&#xD;
             clinically indicated.&#xD;
&#xD;
          -  Life expectancy of at least 2 years, disregarding the diagnosis of cancer.&#xD;
&#xD;
          -  Adequate organ function including normal red and white blood count, platelets, serum&#xD;
             creatinine, bilirubin, and transaminases within normal range of the institution.&#xD;
&#xD;
          -  Patients must be available for and compliant to treatment and follow-up.&#xD;
&#xD;
          -  Patients registered on this trial must be treated and followed up at the participating&#xD;
             center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity reaction to the investigational compounds or incorporated&#xD;
             substances.&#xD;
&#xD;
          -  Local recurrence and/or metastasis of breast cancer.&#xD;
&#xD;
          -  No need of chemotherapy.&#xD;
&#xD;
          -  Pregnant or lactating patients. Patients of childbearing potential must have a&#xD;
             negative pregnancy test (urine or serum) within 14 days prior to registration.&#xD;
&#xD;
          -  Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the uterine cervix).&#xD;
&#xD;
          -  Any other serious medical pathology, such as congestive heart failure; unstable&#xD;
             angina; history of myocardial infarction during the previous year; uncontrolled high&#xD;
             risk arrhythmias.&#xD;
&#xD;
          -  Other serious illness or medical condition that may interfere with the understanding&#xD;
             and giving of informed consent and the conduct of the study.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or any other anti-cancer therapy.&#xD;
&#xD;
          -  Males.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yidong Zhou, Doctor</last_name>
    <phone>86-010-69155200</phone>
    <email>zhouyd@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ru Yao, Doctor</last_name>
    <phone>86-10-69152001</phone>
    <email>yaoru@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yidong Zhou, Doctor</last_name>
      <phone>86-010-69155200</phone>
      <email>zhouyd@pumch.cn</email>
    </contact>
    <investigator>
      <last_name>Yidong Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ru Yao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>ZHOU Yidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>CTC</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

